A flavivirus, named duck tembusu virus (DTMUV), emerged in China in 2010. This virus has caused great economic losses in the poultry industry in China and may pose a threat to public health. As a safe, efficient and convenient
vaccine development strategy,
DNA-based
vaccines have become a popular approach for both human and veterinary applications. Attenuated bacteria have been widely used as vehicles to deliver
heterologous antigens to the immune system. Thus, an efficient and low-cost oral delivery
DNA vaccine SL7207 (pVAX1-SME) based on envelope
proteins (prM and E) of DTMUV and attenuated Salmonella typhimurium aroA- strain SL7207 was developed and evaluated in this study. The prM and
E antigen proteins were successfully expressed from the
vaccine SL7207 (pVAX1-SME) both in vitro and in vivo. High titers of the specific antibody against the DTMUV-E
protein and the
neutralizing antibody against the DTMUV virus were both detected after vaccination with SL7207 (pVAX1-SME). Ducks orally vaccinated with the SL7207 (pVAX-SME)
vaccine were efficiently protected from lethal DTMUV
infection in this study. Taken together, we demonstrated that prM and E
proteins of DTMUV possess strong immunogenicity against the DTMUV
infection. Moreover, an oral delivery of the
DNA vaccine SL7207 (pVAX1-SME) utilizing Salmonella SL7207 was an efficient way to protect the ducks against DTMUV
infection and provides an economic and fast
vaccine delivery strategy for a large-scale clinical use.